CheckpointPx is a newly developed AI based biomarker to predict ICI response in unresectable, locally advanced and metastatic NSCLC patients, using routine baseline radiology scans. Now available for Research Use Only.
CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC).
CheckpointPx, an interpretable radiology AI tool, predicts checkpoint blockade benefit independent of PD-L1 status in non-small cell lung cancers (NSCLC): A multi-institutional validation study
Radiomic Signature Identifies Outcomes and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC)
Interested in seeing our biomarkers in action? Try it out with your data.
Send us a lung CT scan and stop by booth # 1223, to see the results. Learn how we build explainable AI biomarkers that quantify biological tumor properties.
